Compare Cytokinetics Inc (CYTK) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Starbucks Corp — how do they compare? Cytokinetics Inc trades at $76.58 (market cap $10.63B), while Starbucks Corp trades at $107.3 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 11.4× Cytokinetics Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SBUX | |
|---|---|---|
Market Cap | $10.63B | $121.59B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $108.37 |
52-Week Low | $34.31 | $78.46 |
Enterprise Value | $10.74B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Starbucks (SBUX) trades at $104.65, down 0.88% on the day, with technical indicators neutral and support near $104. The company reported mixed quarterly EPS results, beating in Q1 and Q2 2026 but missing in Q4 2025, while raising its fiscal 2026 outlook. Revenue grew to $37.18B in 2025, but net income fell to $1.86B, compressing margins. Analyst consensus is a Buy with a $113.60 price target, citing a traffic recovery and cost initiatives.
The outlook hinges on sustaining sales momentum and margin expansion amid high valuation multiples. Risks include execution on turnaround plans, competitive pressure, and debt levels. Upside potential exists if earnings recovery continues, but investors face volatility from macroeconomic headwinds and premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
